Document:

Exhibit 1024

		

			

		

		
			Exhibit 10.24
		

		
			 
		

		
			November 13, 2019
		

		
			 
		

		
			By Hand
		

		
			 
		

		
			Stephen F. Mahoney
		

		
			89 Woodland Street
		

		
			Sherborn, MA  01770
		

		
			 
		

		
			Dear Steve:
		

		
			 
		

		
			The purpose of this letter agreement (“Agreement”) is to confirm the terms of your separation from Kiniksa Pharmaceuticals Corp. (“Kiniksa” or the “Company”).1  Unless you rescind your assent as set forth in Section 6(iii) below, this Agreement shall be effective on the eighth (8th) day after you sign it (the “Effective Date”), at which time it shall become final and binding on all parties.  
		

		
			 
		

		
			1.            Transitional Employment/Separation Date/Board Resignations.    
		

		
			 
		

		
			(i)           Your employment with the Company shall separate effective December 31, 2019 (the “Separation Date”).
		

		
			 
		

		
			(ii)          As of November 15, 2019 (the “Transition Date”), you will cease to hold your position as President and Chief Operating Officer of the Company; the period between the Transition Date and your Separation Date is hereinafter referred to as the “Transition Period”).  During the Transition Period you will continue to receive your compensation and continue to participate in the Company’s benefits and programs for which you are eligible and enrolled, although you will not be expected to come into the office or otherwise provide services unless specifically and reasonably requested by the Company. All employment related benefits shall end on December 31, 2019, except as set forth in Paragraph 1(iii) below.  
		

		
			 
		

		
			(iii)         On or about the Separation Date, the Company shall pay your final wages, accrued but unused vacation time and any unreimbursed business expenses in accordance with Company policy and/or applicable law. Provided you timely complete the required election forms (which will be provided to you separately), you also will be eligible to continue receiving group medical and/or dental insurance at your own cost pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”).  You acknowledge that from and after the Separation Date, you shall have no authority to, and agree not to, represent yourself as an employee or agent of the Company.  
		

		
			 
		

		
			(iv)         Immediately upon the [Transition Date] you will be deemed to have resigned from any and all positions held by you, whether as an officer or director of the Company or Kiniksa Pharmaceuticals, Ltd., and/or any of their respective affiliates. At the request and cost of the Company, you hereby agree to sign, execute, make and do all such deeds, documents, acts and things as the Company may reasonably require you to do to effectuate such resignation(s).
		

		
			 
		

		

		
			1    Except for the obligations set forth in Section 2(i)-(iii), which shall be solely the obligations of Kiniksa Pharmaceuticals Corp. and Section 2(iv), which shall be solely the obligation of Kiniksa Pharmaceuticals, Ltd., whenever the terms “Kiniksa Pharmaceuticals Corp.,” “Kiniksa” or the “Company” are used in this Agreement (including, without limitation, Section 6), they shall be deemed to include Kiniksa Pharmaceuticals Corp. and any and all of its divisions, affiliates and subsidiaries and all related entities (including, without limitation, Kiniksa Pharmaceuticals, Ltd.) and its and their directors, officers, employees, agents, successors and assigns.  
		

		
			
		

		
			

		 

		

			

		

		

		
			2.            Consideration.  If you remain employed by the Company until December 31, 2019, do not rescind this Agreement as set forth in Section 6(iii) below, and execute the Affirmation described in Section 9 of this Agreement and attached as Exhibit B, then the Company will provide you with the following in accordance your Amended and Restated Employment Agreement dated May 29, 2018 (the “Employment Agreement” and such payments and benefits collectively, the “Consideration”):
		

		
			 
		

		
			(i)           a lump sum severance payment in the amount of $477,641.06, which is equivalent to your annual base salary, less all applicable income and payroll taxes, deductions and withholdings, and less any amounts you may owe to the Company (the “Severance Payment”), which shall be paid within sixty (60) days of the Separation Date;
		

		
			 
		

		
			(ii)          a one-time, lump-sum bonus payment of $16,500.00, less all applicable income and payroll taxes, deductions and withholdings, and less any amounts you may owe to the Company, (the “One-Time Bonus”), which shall be paid within sixty (60) days of the Separation Date; 
		

		
			 
		

		
			(iii)         a one-time, lump sum post-termination bonus of $214,938.48, which is equivalent to the pro-rata share of your 2019 Target Bonus, less all applicable income and payroll taxes, deductions and withholdings, and less any amounts you may owe to the Company, (the “Post-Termination Bonus”), which will be paid at or around the time that annual bonuses are paid to other executive-level employees of the Company on or before March 15, 2020; and
		

		
			 
		

		
			(iv)         twelve (12) months of accelerated vesting on any time-based unvested equity award(s) as of the Separation Date; for the avoidance of doubt, vesting will not be accelerated on any performance-based or partially performance-based equity awards and the exercisability of any vested equity awards shall continue to be governed by the applicable equity award agreements and plan(s). 
		

		
			 
		

		
			3.            Acknowledgments.  You acknowledge and agree that:
		

		
			 
		

		
			(i)           this Agreement and the Consideration are neither intended to nor shall constitute a severance plan and shall confer no benefit on anyone other than Kiniksa and you; 
		

		
			 
		

		
			(ii)          the Consideration provided for herein is not otherwise due or owing to you under any employment agreement (oral or written); and
		

		
			 
		

		
			(iii)         except for (a) any unpaid regular wages (including accrued but unused vacation time) earned through (and including) the Separation Date, which shall be paid by the Company as set forth in this Agreement and (b) any vested monies due to you pursuant to any retirement programs in which you participate, you have been paid and provided all wages, vacation pay, holiday pay, earned paid sick time, bonuses, commissions and any other form of compensation or benefit that may be due to you now or which would have become due in the future in connection with your employment with or separation of employment from Kiniksa.
		

		
			 
		

		
			4.            Unemployment Insurance.  After the Separation Date, you may seek unemployment benefits.  Decisions regarding eligibility for and amounts of unemployment benefits are made by the relevant state agency, not by Kiniksa.  
		

		
			 
		

		
			5.            Return of Company Property; Confidentiality; Trade Secrets; Non-Disparagement.  You hereby agree to:
		

		
			 
		

		
			(i)           promptly return to Kiniksa all property and documents (whether in hard copy or electronic form) of Kiniksa in your custody and possession on or before the Separation Date; 
		

		
			 
		

		
			(ii)          abide by the terms of your Founder Invention and Non-Disclosure Agreement and your Founder Non-Competition and Non-Solicitation Agreement with the Company, both of which are dated 
		

		
			

		 

		

			

		

		

		
			September 18, 2015 (the “Restrictive Covenant Agreements”), copies of which are attached hereto as Exhibit A (and the terms of which are hereby incorporated into this Agreement by reference). You understand that nothing in this Agreement prohibits you from reporting possible violations of federal law or regulation to any governmental agency or entity, including but not limited to the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency Inspector General, or making other disclosures that are protected under the whistleblower provisions of federal law or regulation.  You understand that you do not need the prior authorization of the Company to make any such reports or disclosures and that you are not required to notify the Company that you have made such reports or disclosures;
		

		
			 
		

		
			(iii)         abide by any applicable common law and/or statutory obligations relating to the protection and non-disclosure of Kiniksa’s trade secrets and/or confidential and proprietary documents and information, and you specifically agree that you will not disclose any confidential or proprietary information that you acquired as an employee of Kiniksa to any other person or entity, or use such information in any manner that is detrimental to the interests of Kiniksa; Further, notwithstanding your confidentiality and nondisclosure obligations, you are hereby advised as follows pursuant to the Defend Trade Secrets Act: “An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order”;  
		

		
			 
		

		
			(iv)         keep confidential and not publicize or disclose the existence and terms of this Agreement, other than to (a) an immediate family member, legal counsel, accountant or financial advisor, provided that any such individual to whom disclosure is made shall be bound by these confidentiality obligations; or (b) a state or federal tax authority or government agency to which disclosure is mandated by applicable state or federal law; and
		

		
			 
		

		
			(v)          not make any statements that are disparaging about or adverse to the business interests of Kiniksa or which are intended to harm the reputation of Kiniksa, including, but not limited to, any statements that disparage any product, service, finances, employees, officers, capability or any other aspect of the business of Kiniksa. Kiniksa hereby agrees to instruct anyone in the role of Chief Executive Officer, Executive Vice President, or Senior Vice President as of the Effective Date not to make any statements that are disparaging about or adverse to you, including, but not limited to, any statements that disparage your capability or performance with the Company.
		

		
			 
		

		
			6.            Release of Claims.  
		

		
			 
		

		
			(i)           You hereby acknowledge and agree that by signing this Agreement and accepting the Consideration, you are waiving your right to assert any form of legal claim against Kiniksa (as defined in footnote number 1 to this Agreement) of any kind whatsoever from the beginning of time through and including the date on which you sign this Agreement, except for claims related to the Company’s failure to perform its obligations under this Agreement.  Your waiver and release is intended to bar any form of legal claim, charge, complaint or any other form of action (jointly referred to as “Claims”) against Kiniksa seeking any form of relief including, without limitation, equitable relief (whether declaratory, injunctive or otherwise), the recovery of any damages or any other form of monetary recovery whatsoever (including, without limitation, back pay, front pay, compensatory damages, emotional distress damages, punitive damages, attorneys’ fees and any other costs) against Kiniksa up through and including the date on which you sign this 
		

		
			

		 

		

			

		

		

		
			Agreement.  You understand that there could be unknown or unanticipated Claims resulting from your employment with Kiniksa and the termination thereof and agree that such Claims are intended to be, and are, included in this waiver and release.
		

		
			 
		

		
			(ii)          Without limiting the foregoing general waiver and release, you specifically waive and release the Company from any Claims arising from or related to your employment relationship with the Company or the termination thereof, including without limitation: 
		

		
			 
		

		
			(a)          Claims under any local, state or federal discrimination, harassment, fair employment practices or other employment related statute, regulation or executive order, including, without limitation, the Massachusetts Fair Employment Practices Act (also known as Chapter 151B), the Age Discrimination in Employment Act (“ADEA”) and Title VII of the Civil Rights Act of 1964, each as they may have been amended through the Effective Date; 
		

		
			 
		

		
			(b)          Claims under any local, state or federal employment related statute, regulation or executive order relating to wages, hours, whistleblowing, leaves of absence or any other terms and conditions of employment, including, without limitation, the Family and Medical Leave Act of 1993, the Worker Adjustment and Retraining Notification (WARN) Act, the Massachusetts Payment of Wages Law (Massachusetts General Laws Chapter 149, §§ 148, 150), Massachusetts General Laws Chapter 149 in its entirety and Massachusetts General Laws Chapter 151 in its entirety (including, without limitation, the sections concerning payment of wages, minimum wage and overtime), each as they may have been amended through the Effective Date. You specifically acknowledge that you are waiving any Claims for unpaid wages under these and other statutes, regulations and executive orders; 
		

		
			 
		

		
			(c)          Claims under any local, state or federal common law theory; and 
		

		
			 
		

		
			(d)          any other Claim arising under other local, state or federal law.
		

		
			 
		

		
			(iii)         Because you are over 40 years of age, you are granted specific rights under the Older Workers Benefit Protection Act (“OWBPA”), which prohibits discrimination on the basis of age.  The release set forth in this Section 6 is intended to release any rights you may have against Kiniksa alleging discrimination on the basis of age.  You have twenty-one (21) days to consider and accept the provisions of this Agreement, and you agree that any changes to this Agreement, whether material or immaterial, will not restart the running of this period.  In addition, you may rescind your assent to this Agreement if, within seven (7) days after the date you sign this Agreement, you deliver a written notice of rescission.  To be effective, such notice of rescission must be postmarked, and sent by certified mail, return receipt requested, or delivered within the seven-day period to Kiniksa Pharmaceuticals Corp., 100 Hayden Avenue, Lexington, MA 02421, Attn: Chief Legal Officer.
		

		
			 
		

		
			(iv)         Consistent with federal and state discrimination laws, nothing in this release shall be deemed to prohibit you from challenging the validity of this release under federal or state discrimination laws or from filing a charge or complaint of age or other employment related discrimination with the Equal Employment Opportunity Commission (“EEOC”) or similar state agency, or from participating in any investigation or proceeding conducted by the EEOC or similar state agency.  Further, nothing in this release or Agreement shall be deemed to limit the Company’s right to seek immediate dismissal of such charge or complaint on the basis that your signing of this Agreement constitutes a full release of any individual rights under federal or state discrimination laws, or the Company’s right to seek restitution or other legal remedies to the extent permitted by law of the economic benefits provided to you under this Agreement in the event that you successfully challenge the validity of this release and prevail in any claim under federal or state discrimination laws.
		

		
			

		 

		

			

		

		

		
			(v)          The general release in this Paragraph 6 shall not limit any right you may have to receive a whistleblower award or bounty for information provided to the Securities and Exchange Commission.  
		

		
			 
		

		
			(vi)         The general release in this Paragraph 6 is not affected or limited by the recitation of the specific releases in this Paragraph 6.
		

		
			 
		

		
			7.            Cooperation.  
		

		
			 
		

		
			(i)           For a period of twelve (12) months after the Separation Date (the “Cooperation Period”), you agree to make yourself available to the Company, upon reasonable notice (either by telephone or, if the Company believes necessary, in person) to assist the Company in any matter relating to the services performed by you during your employment with the Company including, but not limited to, transitioning your duties to others.  The Company will reimburse you for any reasonable, out-of-pocket expenses that you may incur in providing such assistance, so long as you first obtain written pre-approval from the Company’s Chief Legal Officer. 
		

		
			 
		

		
			(ii)          During the Cooperation Period and thereafter, you shall reasonably cooperate with the Company in the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Company employed you, provided, that you will not have an obligation under this paragraph with respect to any claim that you have filed directly against the Company or related persons or entities. Your reasonable cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During the Cooperation Period and thereafter, you also shall reasonably cooperate with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while you were employed by the Company, provided you will not have any obligation under this paragraph with respect to any claim that you have filed directly against the Company or related persons or entities. The Company shall reimburse you for any reasonable out-of-pocket expenses incurred in connection with your performance of obligations pursuant to this Section 7(ii).
		

		
			 
		

		
			8.            No Prior Actions.  You represent that you have not filed or asserted any cause of action, claim, charge or other action or proceeding against Kiniksa, and to the best of your knowledge, no other person, organization or entity has done so on your behalf.
		

		
			 
		

		
			9.            Affirmation of Release of Claims.  On or after the Separation Date, you agree to execute the Affirmation attached as Exhibit B.  You also acknowledge and agree that the release of claims in Section 6 shall be fully effective in the event that you fail or refuse to execute the Affirmation, but that the Company shall have no obligation to provide you with the Consideration until you execute the Affirmation.
		

		
			 
		

		
			10.          Miscellaneous.  
		

		
			 
		

		
			(i)           Except for (a) any equity awards or grants, as may be amended herein; (b) the Restrictive Covenants Agreements; and (c) the Indemnification Agreement between you and Kiniksa Pharmaceuticals, Ltd. dated December 6, 2015, all of which shall remain in full force and effect, this Agreement supersedes any and all prior oral and/or written agreements, and sets forth the entire agreement between Kiniksa and you in respect to your separation from Kiniksa including, without limitation, the Employment Agreement.   
		

		
			 
		

		
			(ii)          No variations or modifications of this Agreement shall be deemed valid unless reduced to writing and signed by Kiniksa and you.  
		

		
			

		 

		

			

		

		

		
			(iii)         The provisions of this Agreement are severable, and if for any reason any part hereof shall be found to be unenforceable, the remaining provisions shall be enforced in full.
		

		
			 
		

		
			(iv)         The validity, interpretation and performance of this Agreement, and any and all other matters relating to your employment and separation of employment from Kiniksa, shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without giving effect to conflict of law principles.  Both parties agree that any action, demand, claim or counterclaim relating to (a) your employment and separation of your employment, and (b) the terms and provisions of this Agreement or to its breach, shall be commenced only and exclusively in the Commonwealth of Massachusetts in a court of competent jurisdiction.  
		

		
			 
		

		
			(v)          Both parties further agree that any such dispute shall be tried by a judge alone, and both parties hereby waive and forever renounce the right to a trial before a civil jury in any such dispute.
		

		
			 
		

		
			It is Kiniksa’s desire and intent to make certain that you fully understand the provisions and effects of this Agreement.  To that end, you have been encouraged and given an opportunity to consult with legal counsel.  By executing this Agreement, you are acknowledging that (a) you have been afforded sufficient time to understand the provisions and effects of this Agreement and to consult with legal counsel; (b) your agreements and obligations under this Agreement are made voluntarily, knowingly and without duress; and (c) neither Kiniksa nor its agents or representatives have made any representations inconsistent with the provisions of this Agreement.
		

		
			 
		

		
			If the foregoing correctly sets forth our arrangement, please sign, date and return the enclosed copy of this Agreement to me within the time frame set forth above.  
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			Remainder of page intentionally left blank.
		

		
			
		

		
			

		 

		

			

		

		

		
			November 13, 2019
		

		
			 
		

		
			KINIKSA PHARMACEUTICALS CORP. 
		

		
			 
		

		
			 
		

		
			/s/ Thomas Beetham
		

		
			Thomas W. Beetham
		

		
			Executive Vice President
		

		
			 
		

		
			 
		

		
			Accepted and Agreed to Under Seal:
		

		
			 
		

		
			 
		

		
			/s/ Stephen F. Mahoney
		

		
			Stephen F. Mahoney
		

		
			 
		

		
			 
		

		
			Dated:  November 13, 2019
		

		
			
		

		
			

		 

		

			

		

		

		
			EXHIBIT A
		

		
			 
		

		
			Founder Invention and Non-Disclosure Agreement
		

		
			and
		

		
			Founder Non-Competition and Non-Solicitation Agreement
		

		
			 
		

		
			 
		

		
			
		

		
			

		 

		

			

		

		

		
			EXHIBIT B
		

		
			AFFIRMATION
		

		
			IN ORDER TO RECEIVE THE CONSIDERATION, YOU MUST SIGN, DATE AND RETURN THIS FORM TO TOM BEETHAM, EVP, CHIEF LEGAL OFFICER AND CORPORATE DEVELOPMENT, KINIKSA PHARMACEUTICALS COPR., 100 HAYDEN AVENUE, LEXINGTON, MA 02421, BUT ONLY AFTER YOUR SEPARATION DATE, AS THAT TERM IS DEFINED IN YOUR AGREEMENT with KINIKSA PHARMACEUTICALS CORP. dated NOVEMBER 13, 2019.    
		

		
			I hereby affirm in its entirety the provisions of the Agreement with Kiniksa Pharmaceuticals Corp. signed by me on November 13, 2019, including, without limitation, the release of claims contained in Section 6 of that Agreement, as if it were executed on the date hereof. I understand this affirmation is intended to release any rights I may have against Kiniksa alleging discrimination on the basis of age.  I further understand and acknowledge that: (i) I have been advised to consult with an attorney prior to executing this affirmation; (ii) I have been given twenty-one (21) days to consider and accept the provisions of this affirmation and I agree that any changes to this affirmation, whether material or immaterial, will not restart the running of this period; (iii) I may rescind my assent to this affirmation if, within seven (7) days after the date you sign this affirmation, I deliver a written notice of rescission, postmarked, and sent by certified mail, return receipt requested, or delivered within the seven-day period to Kiniksa Pharmaceuticals Corp., 100 Hayden Avenue, Lexington, MA 02421, Attn: Chief Legal Officer.  
		

			
					
						 

					
						 

					
						 

					
						 

					
						 

					
						 

					
						 

					
						 

					
						 

					
						 

				
	
					
						 

					
						THIS AFFIRMATION IS INVALID IF SIGNED BEFORE YOUR SEPARATION DATE FROM KINIKSA.

					
						 

					
						 

					
						_______________________________________

					
						Stephen F. Mahoney

					
						 

					
						 

					
						DATE: January____, 2020Exhibit 1025

		
			Exhibit 10.25
		

		
			EMPLOYMENT AGREEMENT 
		

		
			 
		

		
			This Employment Agreement (this “Agreement”) is made and entered into as of August 20, 2018 (the “Effective Date”), by and between Kiniksa Pharmaceuticals Corp., a Delaware corporation (the “Company”), and Qasim Rizvi (the “Employee”).
		

		
			WHEREAS, the operations of the Company and its Affiliates (as defined below) are a complex matter requiring direction and leadership in a variety of arenas;  
		

		
			WHEREAS, the Employee possesses certain experience and expertise that qualify Employee to provide the direction and leadership required by the Company and its Affiliates;  and
		

		
			WHEREAS, wishes to employ the Employee on the terms and conditions set forth in this Agreement, and the Employee wishes to be employed under such terms and conditions. 
		

		
			NOW, THEREFORE, in consideration of the foregoing premises and the mutual promises, terms, provisions and conditions set forth in this Agreement, the Company and Employee hereby agree:
		

		
			1.            Definitions.  Words or phrases that are initially capitalized or are within quotation marks shall have the meanings provided in this Section and as provided elsewhere herein. For purposes of this Agreement, the following definitions apply:
		

		
			(a)          “Affiliates” shall mean all persons and entities directly or indirectly controlling, controlled by or under common control with the Company, where control may be by management authority, contract or equity interest.
		

		
			(b)          “Cause” shall mean:
		

		
			(i)           The Employee’s gross negligence or willful misconduct in performance of Employee’s duties to the Company, where such gross negligence or willful misconduct has resulted in or reasonably could result in material damage to the Company or any of its Affiliates or successors; or
		

		
			(ii)          The Employee’s commission of any act of fraud, embezzlement or professional dishonesty with respect to the business of the Company or any of its Affiliates; or
		

		
			(iii)         The Employee’s commission of a felony or crime involving moral turpitude; or
		

		
			(iv)         The Employee’s material breach of any provision of this Agreement or any other written agreement between Employee and the Company; or
		

		
			(v)          The Employee’s failure to comply with lawful directives of the Company, which has caused or which reasonably could cause damage to the Company or any of its Affiliates or successors.
		

		
			(c)          “Change in Control” shall mean:
		

		
			(i)           a sale of all or substantially all of the Parent’s assets; or 
		

		
			(ii)          any merger, consolidation or other business combination transaction of the Parent with or into another corporation, entity or person, other than a transaction in which the holders of at least a majority of the shares of voting capital shares of the Parent outstanding immediately prior to such transaction continue to hold (either by such shares remaining outstanding or by their being converted into shares of voting capital shares of the surviving entity) a majority of the total voting power represented by the shares of voting capital shares of the Parent (or the surviving entity) outstanding immediately after such transaction; or
		

		
			

		 

		

		
			(iii)         the direct or indirect acquisition (including by way of a tender or exchange offer) by any person, or persons acting as a group, of beneficial ownership or a right to acquire beneficial ownership of shares representing a majority of the voting power of the then outstanding shares of capital shares of the Parent.  Notwithstanding the foregoing, a Change in Control shall not be deemed to occur: 
		

		
			(A)         on account of the acquisition of shares of voting capital shares by any institutional investor or any affiliate thereof or any other person, or persons acting as a group, that acquires the Parent’s shares of voting capital shares in a transaction or series of related transactions that are primarily a private financing transaction for the Parent, or 
		

		
			(B)         solely because the level of ownership held by any institutional investor or any affiliate thereof or any other person, or persons acting as a group (the “Subject Person”), exceeds the designated percentage threshold of the outstanding voting capital shares as a result of a repurchase or other acquisition of voting capital shares by the Parent reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition voting capital shares by the Parent, and after such share acquisition, the Subject Person becomes the owner of any additional voting capital shares that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting capital shares owned by such Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur.
		

		
			(d)          “Code” shall mean the Internal Revenue Code of 1986, as amended, and the rules and regulations promulgated thereunder.
		

		
			(e)          “Employee Benefit Plan” shall have the meaning ascribed to such term in Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended. 
		

		
			(f)           “Confidential Information and Non-Competition Agreement” shall mean the Employee Proprietary Information, Inventions Assignment, Non-Competition and Non-Solicitation Agreement between the Employee and Company dated as of August 20, 2018.
		

		
			(g)          “Parent” shall mean the Company’s parent entity, Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company.
		

		
			(h)          “Parent Board” shall mean the board of directors of the Parent.
		

		
			(i)           “Person” shall mean an individual, a corporation, a limited liability company, an association, a partnership, an estate, a trust and any other entity or organization, other than the Company or any of its Affiliates.
		

		
			2.            Acceptance and Term.  Subject to the terms and conditions set forth in this Agreement, the Company hereby offers, and the Employee hereby accepts, employment and/or continuing employment on an at-will basis.  Subject to earlier termination as hereinafter provided, the Employee’s employment shall continue until terminated pursuant to Section 5 hereof (the “Term”).  
		

		
			3.            Position, Duties and Responsibilities.
		

		
			(a)          During the Term, the Employee shall initially serve the Company as its Senior Vice President,Operations, and shall initially report to Steve Mahoney, President & Chief Operating Officer.  During the Term, the Employee shall be employed by the Company on a full-time basis and shall perform the duties and responsibilities of Employee’s position.  
		

		
			(b)          During the Term, the Employee shall devote Employee’s full business time and Employee’s best efforts, business judgment, skill and knowledge exclusively to the advancement of the business and interests of the Company and its Affiliates and to the discharge of Employee’s duties and responsibilities hereunder.  During the Term, the Employee shall not engage in any other business activity or serve in any industry, trade, 
		

		
			

		 

		

		
			professional, governmental or academic position unless Employee first has obtained consent from the Chief Executive Officer of the Company. 
		

		
			(c)          Immediately upon termination of Employee’s employment with the Company for any reason, Employee will be deemed to resign any and all positions held by Employee, whether as an officer or director of the Company, the Parent or any Affiliate of the Company, or as a member of any committees thereof.
		

		
			4.            Compensation and Benefits.  As compensation for all services performed by the Employee during the Term and subject to the Employee’s performance of Employee’s duties and obligations to the Company and its Affiliates, pursuant to this Agreement or otherwise, the Company shall provide the Employee with the following compensation and benefits:
		

		
			(a)          Base Salary.  The Company shall pay the Employee an annual base salary of $385,000, payable in accordance with the Company’s standard payroll practices and procedures and subject to change from time-to-time in the Company’s sole discretion (such base salary, as from time-to-time changed, the “Base Salary”).
		

		
			(b)          Discretionary Bonus Compensation.  During the Term, the Employee shall be eligible to receive an annual cash bonus (“Discretionary Annual Bonus”) with an initial target level of 35% of Employee’s Base Salary (the “Target Bonus”). The applicable performance goals shall be determined by the Company as soon as practicable at the beginning of each calendar year.  The actual Discretionary Annual Bonus for each calendar year, if any, shall be determined in the sole and absolute discretion of the Company and shall be paid to Employee no later than March 15th of the calendar year immediately following the calendar year in which it was earned.  For the avoidance of doubt, the Company reserves the right to not pay any Discretionary Annual Bonuses even if all performance goals are achieved or exceeded.  
		

		
			(c)          Vacation.  During the Term, the Employee shall be entitled to earn vacation at the rate of four (4) weeks per year, to be taken at such times and intervals as shall be determined by the Employee, subject to the reasonable business needs of the Company.  Vacation shall otherwise be governed by the policies of the Company, as in effect from time-to-time.
		

		
			(d)          Other Benefits.  During the Term, the Employee shall be entitled to participate, to the extent eligible, in any and all Employee Benefit Plans from time-to-time in effect for employees of the Company generally, except to the extent any such Employee Benefit Plan is in a category of benefit otherwise provided to the Employee under this Agreement (e.g., a severance pay plan).  Such participation shall be subject to the terms of the applicable plan documents and generally applicable Company policies.  The Company may alter, modify, add to or discontinue its Employee Benefit Plans at any time as it, in its sole judgment, determines to be appropriate, without recourse by the Employee.  
		

		
			(e)          Business Expenses.  The Company shall pay or reimburse the Employee for all reasonable business expenses incurred or paid by the Employee in the performance of Employee’s duties and responsibilities hereunder, subject to reasonable substantiation and documentation and the Company’s standard expense reimbursement policies and procedures.
		

		
			5.            Termination of Employment and Severance Benefits.  The Employee’s employment with the Company shall terminate under the following circumstances:
		

		
			(a)          Death.  In the event of the Employee’s death, the Employee’s employment hereunder shall immediately and automatically terminate.
		

		
			(b)          Disability.
		

		
			(i)           The Company may terminate the Employee’s employment hereunder, upon notice to the Employee, in the event that the Employee becomes disabled during Employee’s employment hereunder through any illness, injury, accident or condition of either a physical or psychological nature and, as a result, is unable to 
		

		
			

		 

		

		
			perform substantially all of Employee’s duties and responsibilities hereunder, notwithstanding the provision of any reasonable accommodation, for ninety (90) consecutive days.
		

		
			(ii)          The Parent Board may designate another employee to act in the Employee’s place during any period of the Employee’s disability.  Notwithstanding any such designation, the Employee shall continue to receive the Base Salary in accordance with Section 4(a) and benefits in accordance with Section 4(d), to the extent permitted by the then-current terms of the applicable benefit plans, until the Employee becomes eligible for disability income benefits under any disability income plan or until the termination of Employee’s employment, whichever shall first occur.
		

		
			(iii)         While receiving disability income payments under any disability income plan, the Employee shall not be entitled to receive any Base Salary under Section 4(a) hereof, but shall continue to participate in Company benefit plans in accordance with Section 4(d) and the terms of such plans, until the termination of Employee’s employment.
		

		
			(c)          By the Company for Cause.  The Company may terminate the Employee’s employment hereunder for Cause at any time upon written notice to the Employee setting forth in reasonable detail the nature of such Cause. 
		

		
			(d)          By the Company Other than for Cause.  The Company may terminate the Employee’s employment hereunder other than for Cause at any time upon written notice to the Employee.
		

		
			(e)          By the Employee.  The Employee may terminate Employee’s employment hereunder at any time upon forty-five (45) days’ notice to the Company.  In the event of termination of the Employee pursuant to this Section 5(e), the Company may elect to waive the period of notice, or any portion thereof.  
		

		
			6.            Severance Payments and Other Matters Related to Separation from Service.
		

		
			(a)          Final Compensation.  Following the termination of the Employee’s employment for any reason, the Company shall pay to the Employee:  (i) any Base Salary earned but not paid during the final payroll period of the Employee’s employment through the date of termination, (ii) pay for any vacation time earned but not used through the date of termination, (iii) any unpaid Discretionary Annual Bonus due to Employee for the calendar year prior to the year in which the termination occurs, and (iv) any business expenses incurred by the Employee but unreimbursed on the date of termination, provided that such expenses and required substantiation and documentation are submitted within thirty (30) days of termination and that such expenses are reimbursable under Company policy (all of the foregoing, “Final Compensation”).  Any Base Salary and any earned, unused vacation time shall be paid to the Employee at the time required by law, but not later than the Company’s next regular pay date following the date of termination.  Any reimbursable business expenses shall be paid within sixty (60) days following the date that the Employee submits such expenses to the Company.  Other than as expressly provided in Section 6(b), the Company shall have no further obligation to the Employee hereunder.
		

		
			(b)          Severance.  In the event the Employee’s employment terminates pursuant to Section 5(a), 5(b) or 5(d) of this Agreement, in addition to Final Compensation, (i) the vesting of all unvested equity awards of Parent or its Affiliates that vest solely based on the passage of time then held by Employee (including, without limitation, restricted stock, restricted stock units, stock options or other equity-based awards, whether granted to or held by Employee either before or after the date of this Agreement) shall accelerate by twelve (12) months (for the avoidance of doubt, with any equity awards that vest in whole or in part based on the attainment of performance-vesting conditions being governed by the terms of the applicable award agreement); and (ii) the Company shall pay the Employee (A) a lump sum equal to the Base Salary divided by twelve (12), then multiplied by the number of months of the Severance Period (as defined below) (such payment, the “Severance Payment”), (B) the Post-Termination Bonus (as defined below), and (C) an additional one-time bonus of $16,500 (such payment, the “One-Time Bonus”).  Subject to Sections 6(d) and 7(a) of this Agreement (x) the Severance Payment and the One-Time Bonus shall be paid by the sixtieth (60th) day following the date of termination and (y) the Post-Termination Bonus shall be paid at or around the time that annual bonuses are paid to other similarly situated employees of the Company, but in no event later than March 15 of the year following the year in which the Separation from Service occurs; provided that if the termination occurs during the twelve (12) month period following a Change in Control, (i) the 
		

		
			

		 

		

		
			Post-Termination Bonus shall be paid by the sixtieth (60th) day following the date of termination and (ii) notwithstanding the provisions of the Parent’s 2018 Incentive Award Plan, the Parent’s 2015 Equity Incentive Plan or any other equity plan, the Employee shall be immediately 100% fully vested in all unvested equity awards of Parent or its Affiliates that vest solely based on the passage of time (including, without limitation, restricted stock, restricted stock units, stock options or other equity-based awards, whether granted to or held by Employee either before or after the date of this Agreement and for the avoidance of doubt, with any equity awards that vest in whole or in part based on the attainment of performance-vesting conditions being governed by the terms of the applicable award agreement). The “Severance Period” shall be nine (9) months; provided, that if the Employee’s separation from service occurs during the twelve (12) months following a Change in Control, then the Severance Period shall be twelve (12) months. 
		

		
			(c)          Post-Termination Bonus.  For the purposes of this Agreement, the “Post-Termination Bonus” shall be a pro-rata share of the Target Bonus for the calendar year in which the termination occurs; provided that if the termination occurs in the twelve (12) month period following a Change in Control, the Post-Termination Bonus shall be equal to the Target Bonus for the calendar year in which such termination occurs.
		

		
			(d)          Release of Claims.  The Employee’s right to receive the payments and benefits set forth in Section 6(b) is conditioned on the Employee’s signing and returning to the Company (and not revoking) a general release of claims in the form provided by the Company at the time the Employee’s employment is terminated (the “Employee Release”).  The Employee must sign and return the Employee Release, if at all, by the deadline specified therein, which deadline shall in no event be later than the sixtieth (60th) calendar day following the termination date.  The Employee Release shall take effect on the expiration of any revocation period specified therein.
		

		
			(e)          Effect of Termination.  Payment by the Company of Final Compensation and the payments and benefits set forth in Section 6(b) shall constitute the sole obligations of the Company in connection with the termination of the Employee’s employment hereunder.  Except for any right of the Employee to continue medical and dental plan participation in accordance with applicable law, benefits shall terminate pursuant to the terms of the applicable benefit plans based on the date of termination of the Employee’s employment without regard to any of the payments set forth in Section 6(b). 
		

		
			(f)           Survival.  Provisions of this Agreement shall survive any termination if so provided herein or if necessary or desirable to accomplish the purposes of other surviving provisions, including without limitation the obligations of the Employee under Section 8 hereof.  The obligation of the Company to make, and the right of the Employee to retain, any payments or benefits set forth in Section 6(b) is expressly conditioned upon the Employee’s continued full performance of obligations under Section 8 and the Confidential Information and Non-Competition Agreement.
		

		
			7.            Timing of Payments and Section 409A.
		

		
			(a)          Notwithstanding anything to the contrary in this Agreement, if at the time of the Employee’s termination of employment, the Employee is a Specified Employee (as defined below), such amounts that may be subject to the Specified Employee rules set forth at (a)(2)(B)(i) of Section 409A of the Code (“Section 409A”) and payable under Section 6 on account of such Separation from Service (as defined below) that would (but for this provision) be payable within six (6) months following the date of termination, shall instead be paid on the next business day following the expiration of such six (6) month period.
		

		
			(b)          For purposes of this Agreement, “Separation from Service” shall be determined in a manner consistent with subsection (a)(2)(A)(i) of Section 409A, and the term “Specified Employee” shall mean an individual determined by the Company to be a specified employee as defined in subsection (a)(2)(B)(i) of Section 409A.
		

		
			(c)          Each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments.
		

		
			(d)          The Employee’s right to reimbursement for business expenses hereunder shall be subject to the following additional rules: (i) the amount of expenses eligible for reimbursement during any calendar year shall 
		

		
			

		 

		

		
			not affect the expenses eligible for reimbursement in any other taxable year, (ii) reimbursement shall be made not later than December 31 of the calendar year following the calendar year in which the expense was incurred, and (iii) the right to reimbursement is not subject to liquidation or exchange for any other benefit.
		

		
			(e)          In no event shall the Company have any liability relating to any payment or benefit under this Agreement failing to comply with, or be exempt from, the requirements of Section 409A.
		

		
			8.            Confidentiality; Cooperation
		

		
			(a)          Confidentiality and Other Covenants. As a condition of Employee’s employment with the Company, the Employee has executed the Confidential Information and Non-Competition Agreement, which the Company and Employee acknowledge and agree shall be considered a separate contract. In addition, Employee represents and warrants that Employee shall be able to and/or will continue to perform the duties of Employee’s position without utilizing any material confidential and/or proprietary information that Employee may have obtained in connection with employment with any prior employer, and that Employee shall not (i) disclose any such information to the Company, or (ii) induce any Company employee to use any such information, in either case in violation of any confidentiality obligation, whether by agreement, by operation of law or otherwise.
		

		
			(b)          Litigation and Regulatory Cooperation. During and after Employee’s employment, Employee shall reasonably cooperate with the Company in the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Company employed Employee; provided that, the Employee will not have an obligation under this paragraph with respect to any claim that the Employee has filed directly against the Company or related persons or entities. The Employee’s reasonable cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after Employee’s employment, Employee also shall reasonably cooperate with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while Employee was employed by the Company, provided Employee will not have any obligation under this paragraph with respect to any claim that Employee has filed directly against the Company or related persons or entities. The Company shall reimburse Employee for any reasonable out-of-pocket expenses incurred in connection with Employee’s performance of obligations pursuant to this Section 8(b).
		

		
			9.            Section 280G; Limitations on Payment 
		

		
			(a)          If any payment or benefit Employee shall or may receive from the Company or otherwise (a “280G Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then any such 280G Payment provided pursuant to this Agreement (a “Payment”) shall be equal to the Reduced Amount.  The “Reduced Amount” shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Employee’s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the “Reduction Method”) that results in the greatest economic benefit for Employee.  If more than one method of reduction shall result in the same economic benefit, the items so reduced shall be reduced pro rata (the “Pro Rata Reduction Method”).
		

		
			(b)          Notwithstanding any provision of Section 9(a) to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows:  (i) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for Employee as determined on an after-tax basis; (ii) as a second priority, Payments that 
		

		
			

		 

		

		
			are contingent on future events (e.g., being terminated without Cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (iii) as a third priority, Payments that are “deferred compensation” within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A.
		

		
			(c)          Unless Employee and the Company agree on an alternative accounting firm or law firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the change of control transaction shall perform the foregoing calculations.  If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the change of control transaction, the Company shall appoint a nationally recognized accounting or law firm to make the determinations required by this Section 9.  The Company shall bear all expenses with respect to the determinations by such accounting or law firm required to be made hereunder.  The Company shall use commercially reasonable efforts to cause the accounting or law firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to Employee and the Company within fifteen (15) calendar days after the date on which Employee’s right to a 280G Payment becomes reasonably likely to occur (if requested at that time by Employee or the Company) or such other time as requested by Employee or the Company.
		

		
			(d)          If Employee receives a Payment for which the Reduced Amount was determined pursuant to clause (x) of Section 9(a) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, Employee agrees to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of Section 9(a)) so that no portion of the remaining Payment is subject to the Excise Tax.  For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of Section 9(a), Employee shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.
		

		
			(e)          Notwithstanding anything contained herein to the contrary, the requirements of this Section 9 shall apply only to the extent the Company has completed an “initial public offering” which results in the Company’s stock being publicly traded on an applicable public exchange.
		

		
			10.          Indemnification.  The Company shall indemnify the Employee to the extent provided in its then current Certificate of Incorporation or By-Laws.  The Employee agrees to promptly notify the Company of any actual or threatened claim arising out of or as a result of Employee’s employment with the Company.
		

		
			11.          Withholding.  All payments made by the Company under this Agreement shall be reduced by any tax or other amounts required to be withheld by the Company under applicable law.
		

		
			12.          Assignment.
		

		
			(a)          Neither the Company nor the Employee may make any assignment of this Agreement or any interest herein, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement without the consent of the Employee in the event that (i) the Employee is transferred to a position with any of the Affiliates or (ii) the Company shall hereafter effect a reorganization, consolidate with, or merge into, any Person or transfer all or substantially all of its properties or assets to any Person.  This Agreement shall inure to the benefit of and be binding upon the Company and the Employee, their respective successors, executors, administrators, heirs and permitted assigns.
		

		
			(b)          The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place.  As used in this Agreement, “Company” shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid.
		

		
			13.          Severability.  If any covenants or such other provisions of this Agreement are found to be invalid or unenforceable by a final determination of a court of competent jurisdiction, (a) the remaining terms and provisions hereof shall be unimpaired, and (b) the invalid or unenforceable term or provision hereof shall be deemed replaced by 
		

		
			

		 

		

		
			a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision hereof.
		

		
			14.          Waiver.  No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party.  The failure of either party to require the performance of any term or obligation of this Agreement, or the waiver by either party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.  
		

		
			15.          Notices.  Any and all notices, requests, demands and other communications provided for by this Agreement shall be in writing and shall be effective when delivered in person, consigned to a reputable national courier service or deposited in the United States mail, postage prepaid, registered or certified, and addressed to the Employee at Employee’s last known address on the books of the Company or, in the case of the Company, at its principal place of business, attention of the Compensation Committee of the Parent Board with a copy to the attention of the Chief Legal Officer, or to such other address as either party may specify by notice to the other actually received. Any notice so addressed shall be deemed to be given or received (a) if delivered by hand, on the date of such delivery, (b) if mailed by courier or by overnight mail, on the first business day following the date of such mailing, and (c) if mailed by registered or certified mail, on the third business day after the date of such mailing.
		

		
			16.          Entire Agreement.  This Agreement, together with the Confidential Information and Non-Competition Agreement, constitute the entire understanding and agreement of the Company and the Employee regarding the terms and conditions of Employee’s employment with the Company. This Agreement supersedes all prior negotiations, discussions, correspondence, communications, understandings, and agreements between the Company and the Employee (including any offer letter given to Employee) relating to the subject matter of this Agreement. Notwithstanding the foregoing, the Company and the Employee acknowledge that options and other equity awards have been and, subject to the discretion and approval of the Parent Board, may be granted to Employee under and pursuant to the Parent’s 2018 Incentive Award Plan or any additional equity plans of the Parent or its Affiliates, and the award agreements related to such plans (collectively, the “Awards”); and to the extent that the terms of this Agreement (including without limitation, Section 6(b)) accelerate the vesting of any such Awards, then the terms of this Agreement are intended to be in addition to the vesting provisions of such Awards and are not intended to diminish any vesting rights contained in such Awards. 
		

		
			17.          Amendment.  This Agreement may be amended or modified only by a written instrument signed by the Employee and by an expressly authorized representative of the Company.
		

		
			18.          Headings.  The headings and captions in this Agreement are for convenience only and in no way define or describe the scope or content of any provision of this Agreement.
		

		
			19.          Counterparts.  This Agreement may be executed in two or more counterparts, each of which shall be an original and all of which together shall constitute one and the same instrument.
		

		
			20.          Governing Law.  This is a Massachusetts contract and shall be construed and enforced under and be governed in all respects by the laws of the Commonwealth of Massachusetts, without regard to the conflict of laws principles thereof.  The Company and Employee agree that any dispute concerning this Agreement shall be heard exclusively by a court of competent jurisdiction within the Commonwealth of Massachusetts.  By signing below, Employee acknowledges that Employee is subject to the personal jurisdiction of the Massachusetts courts in any county where the Company has operations or facilities.  The Employee and Company  further agree that any such dispute shall be tried by a judge alone, and they hereby waive and forever renounce the right to a trial before a civil jury in any such dispute.
		

		
			[Remainder of Page Intentionally Left Blank]
		

		
			
		

		
			

		 

		

		
			IN WITNESS WHEREOF, this Agreement has been executed as a sealed instrument by the Company, by its duly authorized representative, and by the Employee, as of the date first above written.
		

		
			 
		

			
					
						EMPLOYEE

					
					
						   

					
					
						KINIKSA PHARMACEUTICALS CORP.

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						/s/ Qasim Rizvi

					
					
						 

					
					
						By:

					
					
						/s/ Sanj K. Patel

				
	
					
						Name: Qasim Rizvi

					
					
						 

					
					
						Name:

					
					
						 Sanj K. Patel

				
	
					
						 

					
					
						 

					
					
						Title:

					
					
						Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]